U.S. Stock Market Fluctuation: Syndax Plunges on October 13 Due to IPF Failure, Termination of Development, and Target Price Downgrade
Bitget异动解读2026/10/13 13:46Syndax October 13 Drop Analysis
Keywords: IPF failure, termination of development, target price reduction
1. On October 12, Syndax announced that the phase II IPFMAXPIRe trial of axatilimab for idiopathic pulmonary fibrosis (IPF) did not meet the primary endpoint of annual decline in forced vital capacity, and decided to stop further development of this indication, which reduces the potential indications and revenue expansion for the drug.
2. On October 13, Bank of America Securities maintained a "Buy" rating but lowered Syndax's target price from $26 to $23, reflecting a valuation adjustment after the failure of the IPF trial.
(Disclaimer: This content is a summary collected from publicly available information by AI technology and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Renowned analyst revises outlook: Tech giants' capital expenditures to peak in 2027, cash shortages may be exposed earlier
Ives predicts that tech giants' capital expenditures will peak in 2027, free cash flow will bottom out in the first half of next year, and a cash flow inflection point will be reached in 2029.
Euro advances on ECB rate hike expectations, weaker US Dollar
Crypto prices
More
